## Table 0 ##
Recently Issued Accounting Pronouncements In September 2006, the FASB issued Statement of Financial Accounting Standards No.157, Fair Value Measurements (“SFAS No.157”).
SFAS No.157 establishes a framework for measuring fair value in GAAP, and expands disclosures about fair value measurements.
SFAS No.157 applies under other accounting pronouncements that require or permit fair value measurements.
This statement is effective for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years.
The Company will be required to adopt SFAS No.157 in the first quarter of fiscal year 2008.
We do not expect the adoption of SFAS No.157 to have a material impact on our financial reporting and disclosure.
In February 2007, the FASB issued Statement of Financial Accounting Standards (“SFAS No.159”), “The Fair Value Option for Financial Assets and Financial Liabilities.
” SFAS No.159 allows entities the option to measure eligible financial instruments at fair value as of specified dates.
Such election, which may be applied on an instrument by instrument basis, is typically irrevocable once elected.
SFAS No.159 is effective for fiscal years beginning after November 15, 2007, and early application is allowed under certain circumstances.
Management is currently evaluating the requirements of SFAS No.159 and has not yet determined the impact, if any, on the Company’s consolidated financial statements.
In June 2007, the FASB also ratified EITF 07-3, "Accounting for Nonrefundable Advance Payments for Goods or Services Received for Use in Future Research and Development Activities" ("EITF 07-3").
EITF 07-3 requires that nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities be deferred and capitalized and recognized as an expense as the goods are delivered or the related services are performed.
EITF 07-3 is effective, on a prospective basis, for fiscal years beginning after December 15, 2007 and will be adopted by the Company in the first quarter of fiscal 2008.
The Company does not expect the adoption of EITF 07-3 to have a material effect on the Company's consolidated results of operations and financial condition.
In December 2007, the FASB issued SFAS No.141 (revised 2007), "Business Combinations" ("SFAS 141R").
SFAS 141R establishes principles and requirements for how an acquirer recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed, any noncontrolling interest in the acquiree and the goodwill acquired.
SFAS 141R also establishes disclosure requirements to enable the evaluation of the nature and financial effects of the business combination.
SFAS 141R is effective for fiscal years beginning after December 15, 2008, and will be adopted by the Company in the first quarter of fiscal 2009.
The Company is currently evaluating the potential impact, if any, of the adoption of SFAS 141R on its consolidated results of operations and financial condition.
Table of Contents Hologic, Inc.  Notes to Consolidated Financial Statements (continued) (In thousands, except per share data) location during fiscal 2009.
The Company was responsible for a significant portion of the construction costs and therefore was deemed, for accounting purposes, to be the owner of the building during the construction period, in accordance with ASC 840, Leases, Subsection 40-15-5.
During the year ended September 27, 2008, the Company recorded an additional $4,400 in fair market value of the building, which was completed in fiscal 2008.
This is in addition to the $3,000 fair market value of the land and the $7,700 fair market value related to the building constructed that Cytyc had recorded as of October 22, 2007.
The Company has recorded such fair market value within property and equipment on its Consolidated Balance Sheets.
At September 26, 2009, the Company has recorded $1,508 in accrued expenses and $16,329 in other long-term liabilities related to this obligation in the Consolidated Balance Sheet.
The term of the lease is for a period of approximately ten years with the option to extend for two consecutive five-year terms.
The lease term commenced in May 2008, at which time the Company began transferring the Company’s Costa Rican operations to this facility.
It is expected that this process will be complete by February 2009.
At the completion of the construction period, the Company reviewed the lease for potential sale-leaseback treatment in accordance with ASC 840, Subsection 40, Sale-Leaseback Transactions (formerly SFAS No.98 (“SFAS 98”), Accounting for Leases: Sale-Leaseback Transactions Involving Real Estate, Sales-Type Leases of Real Estate, Definition of the Lease Term, and Initial Direct Costs of Direct Financing Leases—an amendment of Financial Accounting Standards Board (“FASB”) Statements No.13, 66, and 91 and a rescission of FASB Statement No.26 and Technical Bulletin No.79-11).
Based on its analysis, the Company determined that the lease did not qualify for sale-leaseback treatment.
Therefore, the building, leasehold improvements and associated liabilities will remain on the Company’s financial statements throughout the lease term, and the building and leasehold improvements will be depreciated on a straight line basis over their estimated useful lives of 35 years.
Future minimum lease payments, including principal and interest, under this lease were as follows at September 26, 2009:
## Table 1 ##
In addition, as a result of the merger with Cytyc, the Company assumed the obligation to a non-cancelable lease agreement for a building with approximately 146,000 square feet located in Marlborough, Massachusetts, to be principally used as an additional manufacturing facility.
In 2011, the Company will have an option to lease an additional 30,000 square feet.
As part of the lease agreement, the lessor agreed to allow the Company to make significant renovations to the facility to prepare the facility for the Company’s manufacturing needs.
The Company was responsible for a significant amount of the construction costs and therefore was deemed, for accounting purposes, to be the owner of the building during the construction period in accordance with ASC 840-40-15-5.
The $13,200 fair market value of the facility is included within property and equipment, net on the Consolidated Balance Sheet.
At September 26, 2009, the Company has recorded $982 in accrued expenses and
PRUDENTIAL FINANCIAL, INC.  Notes to Consolidated Financial Statements 22.
QUARTERLY RESULTS OF OPERATIONS (UNAUDITED) The unaudited quarterly results of operations for the years ended December 31, 2006 and 2005 are summarized in the table below:
## Table 2 ##
(1) Quarterly earnings per share amounts may not add to the full year amounts due to the averaging of shares.
Results for the first quarter of 2006 include pre-tax expenses of $176 million related to obligations and costs retained in connection with businesses contributed to the retail securities brokerage joint venture with Wachovia, including an increase in the reserve for estimated settlement costs related to market timing issues involving Prudential Equity Group, LLC’s former Prudential Securities operations, with respect to which the Company announced that Prudential Equity Group, LLC had reached a settlement in August 2006.
Results for the second and fourth quarters of 2005 include pre-tax expenses of $136 million and $267 million, respectively, related to obligations and costs retained in connection with businesses contributed to the retail securities brokerage joint venture with Wachovia, including accruals for estimated settlement costs related to the market timing issues described above.
Results for the third quarter of 2005 include an income tax benefit of $720 million, as discussed further in Note 17.
The following table shows the benefits we expect to pay to participants from the plans in the next 10 years and assumes that retirement eligible participants take their benefits immediately.
Almost all of the payments will be made from plan assets and not from company assets.
## Table 3 ##
Assumed health care cost trend rates for the U. S.  retiree health care benefit plan at December 31 are as follows:

<table><tr><td></td><td>2005</td></tr><tr><td>Net income as reported</td><td>$311,219</td></tr><tr><td>Add: Total stock-based employee compensation</td><td></td></tr><tr><td>expense recorded during the year</td><td>925</td></tr><tr><td>Deduct: Total stock-based employee compensation expense</td><td></td></tr><tr><td>determined under fair-value based method for all awards,</td><td></td></tr><tr><td>net of tax effects</td><td>-7,239</td></tr><tr><td>Pro forma net income</td><td>$304,905</td></tr><tr><td>Net income per share as reported:</td><td></td></tr><tr><td>Basic</td><td>$1.44</td></tr><tr><td>Diluted</td><td>$1.43</td></tr><tr><td>Pro forma net income per share:</td><td></td></tr><tr><td>Basic</td><td>$1.41</td></tr><tr><td>Diluted</td><td>$1.40</td></tr></table>
<table><tr><td></td><td>Amount</td></tr><tr><td>Fiscal 2010</td><td>$1,508</td></tr><tr><td>Fiscal 2011</td><td>1,561</td></tr><tr><td>Fiscal 2012</td><td>1,616</td></tr><tr><td>Fiscal 2013</td><td>1,672</td></tr><tr><td>Fiscal 2014</td><td>1,731</td></tr><tr><td>Thereafter</td><td>7,288</td></tr><tr><td>Total minimum payments</td><td>15,376</td></tr><tr><td>Less-amount representing interest</td><td>-6,094</td></tr><tr><td>Total</td><td>$9,282</td></tr></table>
<table><tr><td></td><td colspan="4">Three months ended</td></tr><tr><td></td><td> March 31</td><td> June 30</td><td> September 30</td><td>December 31</td></tr><tr><td></td><td colspan="4">(in millions, except per share amounts)</td></tr><tr><td> 2006</td><td></td><td></td><td></td><td></td></tr><tr><td>Total revenues</td><td>$7,850</td><td>$7,373</td><td>$8,408</td><td>$8,857</td></tr><tr><td>Total benefits and expenses</td><td>6,883</td><td>6,780</td><td>6,938</td><td>7,484</td></tr><tr><td>Income from continuing operations before income taxes and equity in earnings of operating joint ventures</td><td>967</td><td>593</td><td>1,470</td><td>1,373</td></tr><tr><td>Income from continuing operations</td><td>739</td><td>469</td><td>1,137</td><td>1,018</td></tr><tr><td>Net income</td><td>733</td><td>453</td><td>1,205</td><td>1,037</td></tr><tr><td>Basic income from continuing operations per share—Common Stock-1</td><td>1.42</td><td>0.93</td><td>2.29</td><td>1.88</td></tr><tr><td>Diluted income from continuing operations per share—Common Stock-1</td><td>1.39</td><td>0.92</td><td>2.24</td><td>1.85</td></tr><tr><td>Basic net income per share—Common Stock-1</td><td>1.40</td><td>0.90</td><td>2.43</td><td>1.92</td></tr><tr><td>Diluted net income per share—Common Stock-1</td><td>1.38</td><td>0.89</td><td>2.38</td><td>1.88</td></tr><tr><td>Basic and diluted net income per share—Class B Stock</td><td>19.50</td><td>6.50</td><td>18.50</td><td>63.50</td></tr><tr><td> 2005</td><td></td><td></td><td></td><td></td></tr><tr><td>Total revenues</td><td>$7,692</td><td>$8,308</td><td>$7,738</td><td>$7,861</td></tr><tr><td>Total benefits and expenses</td><td>6,419</td><td>7,032</td><td>6,686</td><td>7,174</td></tr><tr><td>Income from continuing operations before income taxes and equity in earnings of operating joint ventures</td><td>1,273</td><td>1,276</td><td>1,052</td><td>687</td></tr><tr><td>Income from continuing operations</td><td>928</td><td>922</td><td>1,379</td><td>393</td></tr><tr><td>Net income</td><td>929</td><td>883</td><td>1,364</td><td>364</td></tr><tr><td>Basic income from continuing operations per share—Common Stock-1</td><td>1.51</td><td>1.58</td><td>2.66</td><td>0.85</td></tr><tr><td>Diluted income from continuing operations per share—Common Stock-1</td><td>1.49</td><td>1.55</td><td>2.62</td><td>0.83</td></tr><tr><td>Basic net income per share—Common Stock-1</td><td>1.51</td><td>1.50</td><td>2.63</td><td>0.79</td></tr><tr><td>Diluted net income per share—Common Stock-1</td><td>1.49</td><td>1.48</td><td>2.59</td><td>0.78</td></tr><tr><td>Basic and diluted net income (loss) per share—Class B Stock</td><td>70.50</td><td>53.50</td><td>11.50</td><td>-16.00</td></tr></table>
<table><tr><td></td><td>U.S. DefinedBenefit</td><td>U.S. RetireeHealth Care</td><td>MedicareSubsidy</td><td>Non-U.S. DefinedBenefit</td></tr><tr><td>2015</td><td>$217</td><td>$36</td><td>$-4</td><td>$76</td></tr><tr><td>2016</td><td>95</td><td>37</td><td>-4</td><td>78</td></tr><tr><td>2017</td><td>91</td><td>39</td><td>-4</td><td>82</td></tr><tr><td>2018</td><td>93</td><td>40</td><td>-5</td><td>85</td></tr><tr><td>2019</td><td>93</td><td>40</td><td>-5</td><td>89</td></tr><tr><td>2020 - 2024</td><td>435</td><td>194</td><td>-9</td><td>501</td></tr></table>

Question: What is the growing rate of net income in the year with the most total revenue in September 30?
Answer: -0.11657